When Cancer Affects Your Vision: Understanding Orbital Metastases
"A closer look at how neuroendocrine tumors can impact the eyes and what it means for treatment and surveillance."
Metastasis, the spread of cancer from its primary site to other parts of the body, can occur in various locations. One rare and often overlooked area is the orbit, the bony socket that houses the eye. Orbital metastases, while uncommon, can present significant challenges, particularly when they originate from midgut neuroendocrine tumors (NETs).
Neuroendocrine tumors are a diverse group of neoplasms arising from neuroendocrine cells, which are found throughout the body. Midgut NETs, specifically, originate in the small intestine and can sometimes spread to distant sites. When these tumors metastasize to the orbit, they can cause a range of visual disturbances and discomfort.
This article delves into the intricacies of orbital metastases from midgut NETs, drawing upon a two-institution experience to shed light on detection, symptoms, and evolving treatment approaches. Understanding this rare manifestation is crucial for both patients and healthcare professionals to ensure timely and effective management.
From Neuroendocrine Cells to Orbital Metastases
The history of gastrointestinal and pancreatic neuroendocrine tumors began in 1870, when Rudolf Heidenhain discovered the neuroendocrine cells associated with these tumors. Siegfried Oberndorfer introduced the term carcinoid in 1907. More recent advances include Scarpa's molecular tumor identification, Modlin and Kidd's identification of the molecular circulosome of neuroendocrine neoplasia, and Califano's identification of key oncogenic dependencies. Orbital metastases from endocrine tumors, particularly differentiated thyroid carcinoma and neuroendocrine tumors, are rare and may present with proptosis, diplopia, pain, or other nonspecific symptoms.
What Are Orbital Metastases and Why Are They Significant?
Orbital metastases refer to the spread of cancer cells to the bony socket surrounding the eye. This occurrence is relatively rare, accounting for only a small percentage of all cancer metastases. However, when it does happen, it can lead to a variety of symptoms that significantly impact a person's quality of life.
- Visual Impairment: Orbital metastases can directly affect vision, causing double vision (diplopia), decreased vision, and even vision loss.
- Physical Discomfort: Symptoms such as proptosis (bulging of the eye), eyelid swelling, and pain can cause considerable physical discomfort.
- Diagnostic Challenges: Detecting orbital metastases can be challenging, as initial symptoms may be subtle or attributed to other causes.
- Treatment Implications: The presence of orbital metastases can alter treatment strategies, requiring a multidisciplinary approach to manage both the primary tumor and the spread to the orbit.
Recent Reviews and Treatment Signals
Recent reviews identify differentiated thyroid carcinoma and neuroendocrine neoplasms as the most common endocrine sources of orbital metastases. Reported symptoms include proptosis, diplopia, pain, and visual impairment, which can mimic inflammatory or primary orbital disorders. A 2024 systematic review of literature published from 1966 through September 2023 examined the diagnostic and therapeutic management of primary orbital neuroendocrine neoplasms. In one reported case of bilateral orbital soft-tissue metastases from a renal neuroendocrine tumor, four cycles of PRRT totaling 22.2 GBq improved skeletal pain, proptosis, and vision, while chromogranin A decreased from 150 to 36.39 ng/mL and progression-free survival reached 18 months.
Limits of Biopsy and Radiation
Management decisions for orbital metastases may not follow a single aggressive pathway. In a reported patient with midgut neuroendocrine tumor metastases, radiation therapy was considered but deferred because of the lesions' proximity to critical structures and the patient's lack of symptoms; close surveillance was chosen instead. Another ophthalmology review reports that, in patients with widespread disease and a new orbital mass, biopsy rarely needs to be performed to confirm metastasis. These examples highlight how symptoms, disease extent, and anatomic risk can limit or change the use of biopsy and radiation.
Rarity Across Studies
Orbital involvement is uncommon across the available reports of neuroendocrine tumors. A review by Makis et al. identified orbital metastases in 4 of 251 neuroendocrine tumors treated with Lu-177 DOTATATE or I-131 MIBG since 2003, representing 1.6%; two patients received Lu-177 DOTATATE and two received I-131 MIBG. Separately, a two-institution experience reported that orbital metastases in midgut neuroendocrine tumor patients were rare, with only 20 cases reported at the time. These figures come from different reviews and patient contexts, so they describe rarity but are not directly interchangeable prevalence estimates.
The Future of Managing Orbital Metastases
The management of orbital metastases from midgut NETs is evolving. While local treatments like radiation therapy remain essential, the integration of systemic therapies, including PRRT, offers new hope for controlling both the primary tumor and its spread. Multidisciplinary care, involving ophthalmologists, oncologists, and radiation specialists, is crucial to optimize patient outcomes. Continued research and collaboration will further refine treatment strategies and improve the quality of life for those affected by this rare condition.